Fourestié V, Bougnoux M E, Ancelle T, Liance M, Roudot-Thoraval F, Naga H, Pairon-Pennachioni M, Rauss A, Lejonc J L
Département des Urgences Médicales, Hôpital Henri Mondor, Creteil, France.
Parasitol Res. 1988;75(1):36-41. doi: 10.1007/BF00931188.
To determine the therapeutic usefulness of benzimidazoles in trichinellosis, 117 patients from a single outbreak were treated either with albendazole alone (N = 59) or with a regimen including tiabendazole followed by flubendazole (N = 58). The criteria of disease activity were evaluated at days 1, 7, 15, and 45. No difference was found between the two groups with regard to the evolution of myalgia, fever, fatigue, new clinical manifestations, or laboratory and serologic data. Both treatment regimens were well tolerated. In all, 30 patients of the albendazole group and 29 of the tiabendazole-flubendazole group were reevaluated 16 months later. Serology was negative in 70% of the albendazole-treated patients vs 34.5% of the tiabendazole-flubendazole-treated patients (P less than 0.01). The muscle biopsy examination of nine patients suggested less parasitic infection in the albendazole group. In conclusion, no difference was noted during the early therapeutic responses to the drugs used, but albendazole might be more effective than the other regimen in treating residual larval infestation estimated 16 months after the onset of the disease.
为确定苯并咪唑类药物在旋毛虫病治疗中的有效性，对单次暴发疫情中的117例患者分别采用单用阿苯达唑（N = 59）或采用包括噻苯达唑后接氟苯达唑的方案进行治疗（N = 58）。在第1、7、15和45天评估疾病活动标准。两组在肌痛、发热、疲劳、新的临床表现或实验室及血清学数据的演变方面未发现差异。两种治疗方案耐受性均良好。共有阿苯达唑组的30例患者和噻苯达唑 - 氟苯达唑组的29例患者在16个月后接受了重新评估。阿苯达唑治疗患者中70%的血清学检测为阴性，而噻苯达唑 - 氟苯达唑治疗患者中这一比例为34.5%（P < 0.01）。对9例患者的肌肉活检检查表明阿苯达唑组的寄生虫感染较少。总之，在对所用药物的早期治疗反应期间未发现差异，但在疾病发作16个月后估计阿苯达唑在治疗残留幼虫感染方面可能比另一种方案更有效。
